The Targeted Agent and Profiling Utilization Registration (TAPUR) study

Description

The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.

Status

Accepting new patients

Primary Study Objective(s)

• To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of participants with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known to be a drug target or to predict sensitivity to a drug.
• To record the treatment-related adverse events experienced by participants.
• To create a prospective database of patient outcomes following treatment of participants with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma that harbors a genomic variant known to be a target of an approved targeted anti-cancer drugs or to predict sensitivity to a drug with a commercially available targeted agent provided by the study.
• To catalogue the commercially available tumor genomic tests used by clinical oncologists in the usual care of patients with advanced cancer.
• To determine the concordance of the treatment plan proposed by the treating oncologist with that recommended by the Molecular Tumor Board in applicable situations.

Core eligibility

Note: This is only a partial list of eligibility criteria.